Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Paraquat Parkinson’s Disease Lawsuits Exposure to the toxic herbicide Paraquat has been linked to a risk of Parkinson's disease.
Gardasil HPV Vaccine Lawsuit Side effects of the Gardasil HPV vaccine have been linked to reports of serious and debilitating autoimmune injuries. Lawyers review cases nationwide.
New Recommendations on Use of Medtronic HVAD Heart Systems Issued For Patients With The Implant Medtronic HVAD Heart Systems were linked to 3,000 deaths, according to FDA records, and the manufacturer removed it from the market in 2021. However, many individuals still have the heart device implanted in their body. November 18, 2022 Irvin Jackson Add Your Comments Following thousands of reported deaths and a number of recalls issued in recent years, federal regulators have issued a series of new recommendations for individuals with an implanted Medtronic Heartwear Ventricular Assist Device (HVAD), which was removed from the market in 2021. The Medtronic HVAD was previously used for individuals at risk of death from end-stage left ventricular heart failure, involving an implanted medical device intended to help pump blood from the heart to the rest of the body. Typically the pump has been used while individuals are waiting for a heart transplant, but the HVAD has been plagued with problems. While there are many life-saving benefits of Medtronic’s HVAD mobility, the devices have been subject to at least 17 Class I recalls over defective components since they were approved by the FDA in November 2012, and the agency removed the HVAD from the market in June 2021, after identifying more than 3,000 report involving patient deaths. However, federal health officials do not recommend doctors remove the HVAD, unless an individual is experiencing problems. Therefore, many individuals face continuing risks from the device. MEDTRONIC MINIMED LAWSUITS Did you or a loved one receive a Medtronic MiniMed insulin pump? Recalled Medtronic MiniMed insulin pumps have been linked to reports of hypoglycemia, hyperglycemia and other serious injuries. Learn More SEE IF YOU QUALIFY FOR COMPENSATION MEDTRONIC MINIMED LAWSUITS Did you or a loved one receive a Medtronic MiniMed insulin pump? Recalled Medtronic MiniMed insulin pumps have been linked to reports of hypoglycemia, hyperglycemia and other serious injuries. Learn More SEE IF YOU QUALIFY FOR COMPENSATION On November 17, the FDA gave patients and healthcare professionals a list of new recommendations for HVAD systems. “Choosing to remove an implanted Medtronic Heartware Ventricular Assist Device (HVAD) System without a medically necessary reason is not recommended at this time,” the FDA recommendations state. “The risks associated with removing an implanted Medtronic HVAD System are higher than the potential benefits. Decisions about removing or exchanging the Medtronic HVAD System should be made by patients and health care providers together, considering the patient’s clinical status and surgical risks.” The FDA’s recommendations for patients included keeping their VAD coordinator aware of any concerns with the devices’ behavior, such as alarms, damage, power and battery issues, and even carrying case wear. It recommends they keep two sources of power connected to their controller at all times and to carry spare batteries, and a backup controller at all times. Many of the recommendations for patients involve taking extreme care in handling, replacing, and monitoring of batteries and other power sources. The FDA indicates Medtronic will be allowed to continue to make replacement components for the devices, despite the recall. The FDA is calling on doctors to make sure their HVAD patients are aware of those recommendations, as well as to be aware of the numerous communications, and medical device corrections Medtronic has released recently, such as modified software being available for backup controllers in case the primary controller fails. The agency also recommends doctors check the device for wear and damage during clinical visits, and urges them to report any adverse or suspected events to the FDA’s MedWatch Adverse Event Reporting System. Medtronic HVAD Problems Last summer, the FDA announced Medtronic was removing its HVAD systems from the market, due to an unreasonable risk of neurological events and increased death rates among patients. However, many individuals still have the device implanted, and the FDA does not recommend they have the Medtronic HVAD removed at the time, if there were no problems detected. According to an August 2021 investigation by ProPublica, FDA inspectors began voicing concerns about Medtronic HVAD systems as early as January 2014, following a HeartWare recall in late December 2013, which was issued because the device could fail and stop pumping, leading to serious injury and death. FDA investigators issued a warning letter a month later, after identifying a number of deficiencies at the HeartWare manufacturing facility in Miami Lakes, Florida, particularly involving the process for making sure that some corrections made to the HVAD actually work. The ProPublica investigation lay the blame at the FDA’s feet, saying the agency allowed more than 19,000 patients to be implanted with the heart pump, most of whom received their implants after the FDA had determined the HVAD did not meet federal safety standards. When the devices were removed from the market in June 2021, the FDA indicated it had received more than 3,000 reports of patient deaths by the end of 2020, all linked to HeartWare implant problems. Tags: Heart Transplant, HeartWare, HVAD, Medical Device Recall, Medtronic More Medtronic MiniMed Lawsuit Stories Medtronic MiniMed Insulin Pump Recall Over Battery Failure Risks October 7, 2024 FDA Issues “Do Not Use” Warning for Recalled Medtronic NIM Endotracheal Tubes July 10, 2024 Medfusion Syringe Pump Recall Issued Over Software Errors March 6, 2024 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (Posted: yesterday) Parties involved in Covidien hernia mesh lawsuits indicate they are ready to meet with a mediator in a couple weeks to begin potential settlement negotiations. MORE ABOUT: HERNIA MESH LAWSUITCovidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)Discovery Deadlines in Covidien Hernia Mesh Lawsuits Extended by MDL Judge (12/12/2024)Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims (11/22/2024) Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: 2 days ago) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025) Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: 3 days ago) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025)
Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (Posted: yesterday) Parties involved in Covidien hernia mesh lawsuits indicate they are ready to meet with a mediator in a couple weeks to begin potential settlement negotiations. MORE ABOUT: HERNIA MESH LAWSUITCovidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)Discovery Deadlines in Covidien Hernia Mesh Lawsuits Extended by MDL Judge (12/12/2024)Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims (11/22/2024)
Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: 2 days ago) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025)
Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: 3 days ago) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025)